Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
May 07, 2021 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
April 28, 2021 07:01 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes
April 28, 2021 07:00 ET
|
Trillium Therapeutics Inc.
TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses...
Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021
April 22, 2021 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day
March 18, 2021 16:05 ET
|
Trillium Therapeutics Inc.
Wide-ranging transformation program completedR&D Day scheduled for April 28, 2021, to provide data updates, and announce strategic priorities and clinical development plan going forward$291.2...
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021
December 07, 2020 16:05 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
November 25, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results
November 16, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
November 12, 2020 16:05 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Announces Formation of Scientific Advisory Board
November 02, 2020 16:15 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...